张琳,李燕,安志杰

• 1:中国疾病预防控制中心免疫规划中心

摘要(Abstract)：

新型冠状病毒病(COVID-19)于2019年底在中国武汉发现,并在全球出现快速传播,世界卫生组织于2020年1月30日宣布COVID-19为国际关注的突发公共卫生事件,2020年3月11日宣布为全球大流行。目前全球科学家正在从多条技术路线包括传统的和新型的技术路线进行COVID-19疫苗研发。本文总结了COVID-19脱氧核糖核酸(Deoxyribonucleic acid, DNA)疫苗研发面临的挑战和研发进展。

关键词(KeyWords)： 新型冠状病毒;2019冠状病毒病;DNA疫苗

Abstract:

Keywords:

基金项目(Foundation): “十三五”国家科技重大专项(2018ZX09734004)

作者(Author): 张琳,李燕,安志杰

参考文献(References)：

• [1]WU F,ZHAO S,YU B,et al.A new coronavirus associated with human respiratory disease in China[J].Nature:International Weekly Journal of Science,2020,579(7798):265-269.
• [2]ZHU N,ZHANG D,WANG W,et al.A novel coronavirus from patients with pneumonia in China,2019[J].New England Journal of Medicine,2020,382(8):727-733.
• [3]WHO.Coronavirus disease(COVID-19)pandemic[EB/OL].(2020-07-22)[2020-07-22].https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
• [4]GISAID.Coronavirus COVID-19 global cases by Johns Hopkins CSSE[EB/OL].(2020-07-21)[2020-07-21].https://www.gisaid.org/epiflu-applications/global-cases-covid-19/.
• [5]WOLFF JA,MALONE RW,WILLIAMS P,et al.Direct gene transfer into mouse muscle in vivo[J].Science,1990,247(4949 Pt 1):1465-1468.
• [6]胡瞬,易有金,胡涛,等.mRNA疫苗的开发及临床研究进展[J].中国生物工程杂志,2019,39(11):105-112.
• [7]SUSCHAK JJ,WILLIAMS JA,SCHMALJOHN CS.Advancements in DNA vaccine vectors,nonmechanical delivery methods,and molecular adjuvants to increase immunogenicity[J].Human Vaccines&Immunotherapeutics,2017,13(12):2837-2848.
• [8]赵琪,安静,陈辉.登革病毒DNA疫苗的研究进展[J].军事医学,2016,40(11):923-926.
• [9]CSORDAS BG,CUNHA RC,GARCIA MV,et al.Molecular characterization of the recombinant protein RmLTI-BmCG-LTB:protective immunity against Rhipicephalus(Boophilus)microplus[J].PLoS One,2018,13(2):e0191596.
• [10]FYNAN EF,LU S,ROBINSON HL.One group's historical reflections on DNA vaccine development[J].Human Gene Therapy,2018,29(9):966-970.
• [11]KLINMAN DM,YAMSHCHIKOV G,ISHIGATSUBO Y.Contribution of CpG motifs to the immunogenicity of DNA vaccines[J].Journal of Immunology(Baltimore,MD:1950),1997,158(8):3635-3639.
• [12]LI L,SAADE F,PETROVSKY N.The future of human DNA vaccines[J].Journal of Biotechnology,2012,162(2-3):171-182.
• [13]TROLLET C,PEREIRA Y,BURGAIN A,et al.Generationof high-titer neutralizing antibodies against botulinum toxins A,B,and E by DNA electrotransfer[J].Infection and Immunity,2009,77(5):2221-2229.
• [14]ZHU Y,LU F,DAI Y,et al.Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines[J].Vaccine,2010,28(32):5347-5355.
• [15]TENBUSCH M,GRUNWALD T,NIEZOLD T,et al.Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+)T-cell responses and immune effector mechanisms following DNA electroporation in mice[J].Vaccine,2010,28(19):3273-3277.
• [16]SHAKUNTALA M,GARCIA-HAND D,CAPPELLO S,et al.Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses[J].Vaccine,2008,26(40):5083-5094.
• [17]CHEUNG YK,CHENG SCS,SIN FWY,et al.Plasmid encoding papillomavirus type 16(HPV16)DNA constructed with codon optimization improved the immunogenicity against HPV infection[J].Vaccine,2004,23(5):629-638.
• [18]DOBANO C,SEDEGAH M,ROGERS WO,et al.Plasmodium:mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity[J].Experimental Parasitology,2009,122(2):112-123.
• [19]TEMPERTON NJ,QUENELLE DC,LAWSON KM,et al.Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine:adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides[J].Journal of Medical Virology,2003,70(1):86-90.
• [20]KHOSROSHAHI KH,GHAFFARIFAR F,SHARIFI Z,et al.Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of toxoplasma gondii[J].Parasitology Research,2012,111(1):403-411.
• [21]ARA Y,SAITO T,TAKAGI T,et al.Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system[J].Immunology,2001,103(1):98-105.
• [22]SINGH M,BRIONES M,OTT G,et al.Cationic microparticles:a potent delivery system for DNA vaccines[J].Proceedings of the National Academy of Sciences of the United States of America,2000,97(2):811-816.
• [23]SINGH M,VAJDY M,GARDNER J,et al.Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity[J].Vaccine,2001,20(3):594-602.
• [24]KARKADA M,WEIR GM,QUINTON T,et al.A liposome-based platform,VacciMax,and its modified water-free platform DepoVax enhance efficacy of in vivonucleic acid delivery[J].Vaccine,2010,28(38):6176-6182.
• [25]DOMINIKA H,MATTHIAS B.DNA vaccines-how far from clinical use?[J].International Journal of Molecular Sciences,2018,19(11):3605.
• [26]KULKARNI V,ROSATI M,JALAH R,et al.DNA vaccination by mtradermal electroporation induces longlasting immune responses in rhesus macaques[J].Journal of Medical Primatology,2014,43(5):329-340.
• [27]KUTZLER MA,WEINER DB.Developing DNA vaccines that call to dendritic cells[J].The Journal of Clinical Investigation,2004,114(9):1241-1244.
• [28]CHO JH,YOUN JW,SUNG YC.Cross-priming as a predominant mechanism for inducing CD8(+)T cell responses in gene gun DNA immunization[J].Journal of Immunology(Baltimore,MD:1950),2001,167(10):5549-5557.
• [29]VASAN S,HURLEY A,SCHLESINGER SJ,et al.In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers[J].PLoS One,2011,6(5):e19252.
• [30]LOW L,MANDER A,MCCANN K,et al.DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer[J].Human Gene Therapy,2009,20(11):1269-1278.
• [31]KIM TJ,JIN HT,HUR SY,et al.Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients[J].Nature Communications,2014,5:5317.
• [32]YU J,TOSTANOSKI LH,PETER L,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques[J].Science(New York),2020,eabc6284.
• [33]SMITH RFT,PATEL A,RAMOS S,et al.Immunogenicity of a DNA vaccine candidate for COVID-19[J].Nature Communications,2020,11(14):727-733.
• [34]卜文.重组人乳头瘤病毒九价疫苗的安全性和免疫原性研究[D].泰安:山东农业大学,2018.
• [35]黄仕和,封多佳.疫苗安全性述评[J].中国执业药师,2012,9(9):21-24+64.
• [36]王永生.SARS-CoV S DNA疫苗经鼻腔免疫Balb/c小鼠后的免疫应答特征[D].广州:中山大学,2006.
• [37]吴雪琼,栾翔凌,熊志红,等.SARS-CoV基因疫苗的构建及免疫原性初步研究[J].中国现代医学杂志,2008,18(5):531-534+538.
• [38]MARTIN JE,LOUDER MK,HOLMAN LA,et al.A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial[J].Vaccine,2008,26(50):6338-6343.
• [39]MODJARRAD K,ROBERTS CC,MILLS KT,et al.Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine:a phase 1,open-label,single-arm,dose-escalation trial[J].The Lancet Infectious Diseases,2019,19(9):1013-1022.
• [40]艾防中心.艾防中心承担的艾滋病疫苗研究Ⅱa期临床试验完成招募和疫苗接种[EB/OL].(2019-11-01)[2020-06-15].http://ncaids.chinacdc.cn/zxzx/zxdteff/201911/t20191101 206626.htm.
• [41]艾防中心.国家科技重大专项自主研制的艾滋病疫苗II期临床试验全面启动[EB/OL].(2019-06-05)[20202-06-19].http://www.chinacdc.cn/zxdt/201906/t20190605_203095.html.
• [42]姜永萍.我国首个DNA疫苗获得批准[J].农业知识,2018,(24):34-35.
• [43]ELLIOTT STC,KEATON AA,CHU JD,et al.A synthetic micro-consensus DNA vaccine generates comprehensive influenza A H3N2 immunity and protects mice against lethal challenge by multiple H3N2 viruses[J].Human Gene Therapy,2018,29(9):1044-1055.
• [44]FAUREZ F,DORY D,LE MOIGNE V,et al.Biosafety of DNA vaccines:new generation of DNA vectors and current knowledge on the fate of plasmids after injection[J].Vaccine,2010,28(23):3888-3895.
• [45]GILKESON GS,RUIZ P,HOWELL D,et al.Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA[J].Clinical Immunology and Immunopathology,1993,68(3):283-292.
• [46]MOR G,YAMSHCHIKOV G,SEDEGAH M,et al.Induction of neonatal tolerance by plasmid DNA vaccination of mice[J].The Journal of Clinical Investigation,1996,98(12):2700-2705.
• [47]KUTZLER MA,WEINER DB.DNA vaccines:ready for prime time?[J].Nat Rev Genet,2008,9(10):776-788.
• [48]MAIRHOFER J,PFAFFENZELLER I,MERZ D,et al.A novel antibiotic free plasmid selection system:advances in safe and efficient DNA therapy[J].Biotechnology Journal,2008,3(1):83-89.
• [49]Inovio.Safety,tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers[EB/OL].(2020-06-05)[2020-06-29].https://clinicaltrials.gov/ct2/show/NCT04336410?term=INO-4800&draw=2&rank=1.
• [50]Inovio.Inovio expands manufacturing of COVID-19DNA vaccine INO-4800 with new funding from CEPI[EB/OL].(2020-04-30)[2020-05-15].http://s23.q4cdn.com/479936946/files/doc_news/INOVIO-ExpandsManufacturing-of-CO VID-19-DN A-Vaccine-INO-4800-With-New-Funding-from-CEPI-20 20.pdf.
• [51]Inovio.Safety,tolerability and immunogenicity of INO-4800 followed by electroporation in healthy volunteers for COVID-19[EB/OL].(2020-06-25)[2020-06-29].https://clinicaltrials.gov/ct2/show/NCT04447781?term=INO-4800&draw=2&rank=2.
• [52]Inovio.Inovio announces positive interim phase 1 data for INO-4800 vaccine for COVID-19[EB/OL].(2020-06-30)[2020-07-22].http://s23.q4cdn.com/479936946/file s/doc news/INOVIO-Announces-Positive-Interim-Phase-1-DataFor-INO-4800-Vaccine-for-COVID-19-2020.pdf.
• [53]Genexine.Genexine,COVID-19 preventive vaccine,GX-19,clinical 1/2 phase approval[EB/OL].(2020-06-11)[2020-06-22].http://www.genexine.com/m62 view.php?idx=157&cate=1&year=.
• [54]Symvivo.Evaluating the safety,tolerability and immunogenicity of bacTRL-Spike vaccine for prevention of COVID-19[EB/OL].(2020-06-29)[2020-06-29].https://clinicaltrials.gov/ct2/show/NCT04 3 34980.
• [55]Inc AnGes.AnGes and Osaka University launch joint DNA vaccine development against coronavirus disease2019(COVID-19)[EB/OL].(2020-03-05)[2020-05-05].https://www.anges.co.jp/en/pdf.php?pdf=00 3Mk7IxCg7spY u6nteDj80QPMCznRi2.pdf.
• [56]Bio Takara.Takara Bio to support development of novel coronavirus vaccine undertaken by Osaka University Group[EB/OL].(2020-03-06)[2020-05-05].https://ir.takara-bio.co.jp/en/news all/news Release/news Relea se201889409321505118082820200306.html.
• [57]AnGes.Study of COVID-19 DNA vaccine(AG0301-COVID19)[EB/OL].(2020-07-0 9)[2020-07-22].https://clinicaltrials.gov/ct2/show/NCT04463472?term=Anges+COVID-19+vaccine.
• [58]Zydus.Zydus starts human dosing of its vaccine'Zy CoV-D'[EB/OL].(2020-07-05)[2020-07-22].https://zyduscadila.com/public/pdf/pressrelease/Press-Release-Zydus-CoV-D.pdf.
• [59]Cadila Zydus.Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus,2019-nCoV(COVID-19)[EB/OL].(2020-02-15)[2020-05-15].https://zyduscadila.com/public/pdf/pressrelease/Zydus Cadila launches a fast tracked programme to develop_vaccine for the novel coronavirus 2019-nCoVCOVID-19).pdf.
• [60]OncoSec.OncoSec collaborates with Providence Cancer Institute to conduct first-in-human trial of OncoSec's CORVaxl2,an investigational vaccine to prevent COVID-19,combining an enhanced"spike"DNA sequence and TAVOTM[EB/OL].(2020-04-06)[2020-05-15].https://ir.oncosec.com/press-releases/detail/2042/oncoseccollaborates-with-providence-cancer-institute-to.
• [61]Biologics Cobra.Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine[EB/OL].(2020-03-30)[2020-05-15].https://www.cobrabio.com/New s/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine.
• [62]Institutet Karolinska.The OPENCORONA consortia will develop a vaccine that protects against SARS-CoV-2infection and/or disease in a phase I clinical trial in 24months[EB/OL].(2020-04)[2020-05-14].https://ki.se/en/research/opencorona.
• [63]Stony Brook NY.Applied DNA Sciences Subsidiary,LineaRx,and Takis Biotech collaborate for development of a linear DNA vaccine candidate against Wuhan coronavirus 2019-nCoV[EB/OL].(2020-02-07)[2020-06-15].https://adnas.com/coronoavirus-applied-dna-linearxtakis-biotech-vaccine/.
• [64]Stony Brook NY.Applied DNA ships COVID-19LinearDNATM vaccine candidates to Italian Development Partner to begin preclinical animal testing[EB/OL].(2020-04-15)[2020-05-15].https://www.biospace.com/article/releases/applied-dna-ships-covid-19-lineardnavaccine-candidates-to-italian-development-partner-tobegin-preclinical-animal-testing/.
• [65]Medeiros Danielle.Press release:Entos Pharmaceuticals partners with EpiVax to develop a pan-coronavirus DNA vaccine[EB/OL].(2020-04-28)[2020-06-15].https://epivax.com/featured/press-release-entos-pharmaceuticalspartners-with-epivax-to-develop-a-pan-coronavirus-dnavaccine.
• [66]Pharmaceuticals Entos.Entos Pharmaceuticals is developing a DNA vaccine against COVID-19 using its Fusogenix Nanomedicine Platform[EB/OL].(2020-03-18)[2020-05-15].https://www.entospharma.com/news/entospharmaceuticals-is-developing-a-dna-vaccine-againstcovid-19-using-its-fusogenix-nanomedicine-platform.
• [67]Keown Alex.GSK and Sanofi join forces to develop a COVID-19 vaccine[EB/OL].(2020-04-14)[2020-05-151.https://www.biospace.com/article/gsk-and-sanofi-joinforces-to-develop-a-covid-19-vaccine/.
• [68]BioNet.BioNet in Thailand is developing a COVID-19GENE-based vaccine(COVIGEN)encoding the S(Spike)protein of SARS-CoV-2[EB/OL].(2020-03-11)[2020-05-15].http://www.bionet-asia.com/media/news-events/.
• [69]Scancell.Scancell to initiate development of novel DNA vaccine against COVID-19[EB/OL].(2020-04-24)[2020-05-15].https://www.scancell.co.uk/D ata/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf.
• [70]Stampa Comunicato.IL vaccino Italiano contro COVID-19:Accordo Fra Takis e Rottapharm Biotech per lo sviluppo[EB/OL].(2020-06-03)[2020-06-16].http://www.takisbiotech.it/images/doc/CS Takis RottapharmBiotech_3.06.2020.pdf.
• [71]第一财经.上海研发新冠人源细胞疫苗,科学家已亲试第一针[EB/OL].(2020-03-08)[2020-06-24].https://tech.sina.cn/2020-0 3-08/detail-iimxyqvz8 841241.d.html.
• [72]Systems Pan Genome.UW-Madison Spinoff pursues COVID-19 vaccine[EB/OL].(2020-03-30)[2020-07-22].https://pangenosys.com/2020/0 3/https-www-trialsitenewscom-uw-madison-spinoff-purses-covid-19-vaccineintroducing-pan-genome-sy stems/.
• [73]HYANG KJ,JOSHY J.DNA vaccines against influenza viruses[J].Current Topics in Microbiology and Immunology,2009,333:197-210.
• [74]TEBAS P,KRAYNYAK KA,PATEL A,et al.Intradermal SynCon~?Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers[J].The Journal of Infectious Diseases,2019,220(3):400-410.